SwedenBio Snapshot Shows Vibrant Ecosystem
First ‘State Of Play’ Report For Swedish Life Sciences In Four Years
Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.
You may also be interested in...
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.